Sweden's primary regulatory authority is the Medical Products Agency (Läkemedelsverket, MPA), which oversees the approval, surveillance, and control of pharmaceuticals, medical devices, diagnostics, and digital health products. As an EU member state, Sweden operates within the framework established by EU legislation, including Regulation (EU) 2017/745 (MDR) for medical devices, Regulation (EU) 2017/746 (IVDR) for in vitro diagnostics, and Directive 2001/83/EC for medicinal products. Pharmaceutical marketing authorisations are granted either through the European Medicines Agency (EMA) via the centralised procedure, through the mutual recognition or decentralised procedures coordinated with other EU member states, or through a purely national procedure administered by the MPA for products intended solely for the Swedish market. The MPA also acts as a notified body designating authority and market surveillance authority under the MDR and IVDR frameworks.
Applicants must submit dossiers in the Common Technical Document (CTD) format for pharmaceuticals, aligning with ICH guidelines. For medical devices and IVDs, conformity assessment under the relevant EU regulation is required, typically involving a CE mark issued by an EU-recognised Notified Body before market placement. A local authorised representative established within the EU is mandatory for manufacturers based outside the EU. Sweden has actively implemented the EU Medical Device Coordination Group (MDCG) guidance and has reinforced post-market surveillance obligations following the full application of MDR and IVDR. Recent reforms include strengthened eHealth and digital health regulatory guidance, with the MPA issuing clarifications on when software qualifies as a medical device under the MDR. Sweden also participates in the European Health Data Space initiative, signalling an evolving regulatory posture toward data-driven health products.
Public procurement in Sweden is primarily governed by the Public Procurement Act (Lagen om offentlig upphandling, LOU, 2016:1145), which transposes EU procurement directives into national law. Healthcare is largely administered at the regional level, with Sweden's 21 regional councils (regioner) responsible for financing and delivering most health services, including hospital procurement. Each region conducts its own tenders for medical devices, diagnostics, pharmaceuticals, and digital health solutions, though national coordination is facilitated by the National Government Service Centre (Statens servicecenter) and sector-specific bodies. For pharmaceuticals, the Dental and Pharmaceutical Benefits Agency (Tandvards- och lakemedelsformansverket, TLV) conducts health technology assessments (HTA) and determines whether a product qualifies for reimbursement under the national pharmaceutical benefits scheme. Pricing negotiations for reimbursed products involve the TLV and, in some cases, managed entry agreements with the MPA and regional payers. The Swedish Association of Local Authorities and Regions (Sveriges Kommuner och Regioner, SKR) plays a coordinating role in facilitating joint procurement frameworks across regions, particularly for high-value diagnostics and medical technology.
The private healthcare sector in Sweden, while smaller than the public sector, is growing and represents an additional procurement channel, particularly for digital health solutions, diagnostics, and specialist medical devices. Private providers must comply with the same regulatory requirements as public entities and frequently participate in regional procurement frameworks. Sweden is a high-income country and does not rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi for standard health product acquisition. However, Swedish procurement entities may participate in joint EU procurement mechanisms, such as those coordinated by the European Commission for pandemic-related products. Local manufacturing preference policies are not a defining feature of Swedish procurement, as EU public procurement rules generally prohibit discrimination based on origin within the European Economic Area; however, sustainability criteria and life-cycle costing are increasingly incorporated into tender evaluation, and Sweden's broader industrial and innovation policy encourages domestic health technology development through bodies such as Vinnova and Sweden Medtech industry partnerships.
This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.
Generate a free Market Brief for Sweden →